Posted by Michael Wonder on 10 Nov 2022
MHRA extends Cosentyx licence for paediatric arthritis
9 November 2022 - Data demonstrates that secukinumab shows a significantly longer time to flare versus placebo
Novartis has announced that the UK MHRA has granted marketing authorisation for Cosentyx – also known as secukinumab.
